CXCL9

Overview

CXCL9 is an IFN-gamma-induced CXCR3 ligand that directs CD8 T cell and NK cell recruitment into inflamed and tumor tissues.

Alterations observed in the corpus

  • Included in the 20-gene Immunologic Constant of Rejection (ICR) signature as a CXCR3/CCR5 chemokine ligand, alongside CCL5 and CXCL10, applied to the 348-patient AC-ICAM colon cancer cohort PMID:37202560.
  • CXCL9 was identified as an APC chemoattraction marker in spatial transcriptomic profiling (GeoMx WTA) of fallopian tube HGSOC precursor lesions; CXCL9 expression used to define infiltrating immune-cell populations and their spatial relationship to HLA-E+ epithelium across the p53-signature → STIC.I → STIC.C → invasive cancer axis PMID:39386723.

Cancer types (linked)

  • Colon adenocarcinoma — CXCL9 contributes to ICR-based prognostic clustering independent of CMS and MSI PMID:37202560.
  • OV (HGSOC) / fallopian tube precursors — CXCL9 expression used as APC chemoattraction marker to characterize immune compartments across HGSOC progression stages PMID:39386723.

Co-occurrence and mutual exclusivity

  • Co-expressed with the ICR Th1/chemokine/effector module in ICR-high colon tumors PMID:37202560.

Therapeutic relevance

  • No direct CXCL9-targeted therapy is evaluated; it contributes to the prognostic ICR module PMID:37202560.

Open questions

  • Independent contribution of CXCL9 vs the ICR module is not dissected PMID:37202560.

Sources

This page was processed by crosslinker on 2026-05-04.